Literature DB >> 10551395

Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.

L P Zhang1, T Takahara, Y Yata, K Furui, B Jin, N Kawada, A Watanabe.   

Abstract

BACKGROUND/AIMS: Plasminogen activators and plasminogen activator inhibitors are important regulators of the balance between the proteolytic and antiproteolytic activities that determine extracellular matrix turnover. We examined the expression of plasminogen activator-plasmin system components in experimental liver fibrosis of rats.
METHODS: Liver fibrosis was produced in rats by injecting carbon tetrachloride for 6 to 12 weeks. Gene expression for plasminogen activator inhibitor-1 (PAI-1), urokinase and tissue plasminogen activators (uPA and tPA), urokinase plasminogen activator receptor (uPAR), and transforming growth factor-beta1 (TGF-beta1) was examined by Northern analysis. Western analysis was performed to detect protein expression of PAI-1, uPA and uPAR. An immunohistochemical study was performed to detect the localization of PAI-1. Additionally, primary cultured liver cells were examined by Northern and Western analyses for this protein with or without prior incubation with TGF-beta1.
RESULTS: At 6 weeks, when fibrosis had occurred, uPA and uPAR mRNAs had increased 2.8-fold and 1.8-fold, respectively; PAI-1 and tPA mRNA levels were unchanged. At the cirrhotic stage (9 to 12 weeks), mRNA levels for PAI-1, uPA, uPAR and tPA were all increased. Western analysis also showed increased uPA and uPAR expressions in fibrotic liver, and increased PAI-1, uPA and uPAR expressions in cirrhotic liver. PAI-1 protein was also demonstrated immunohistochemically along sinusoids, vessels, and bile duct cells of normal and fibrotic liver. In liver cell cultures, Kupffer cells, hepatocytes, and especially stellate cells, expressed PAI-1. Expression was enhanced in stellate cells cultured from fibrotic or cirrhotic liver or stimulated in vitro with TGF-beta1.
CONCLUSION: Though increased uPA and uPAR may act on matrix degradation in fibrotic liver, increased PAI-1 together with uPA, uPAR and tPA are associated with overall inhibition of matrix degradation in cirrhotic liver. Hepatic stellate cells are an important source of PAI-1 during liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551395     DOI: 10.1016/s0168-8278(99)80351-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  39 in total

1.  PAI-1, fibrosis, and the elusive provisional fibrin matrix.

Authors:  D J Loskutoff; J P Quigley
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

2.  Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver.

Authors:  J G Fan; L H Chen; Z J Xu; M D Zeng
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

3.  Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts.

Authors:  Jianyong Zhong; Hai-Chun Yang; Valentina Kon; Agnes B Fogo; Daniel A Lawrence; Ji Ma
Journal:  Lab Invest       Date:  2014-03-31       Impact factor: 5.662

Review 4.  Mechanisms of hepatic fibrogenesis.

Authors:  Scott L Friedman
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

5.  Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells.

Authors:  Xingjun Liu; Wei Wang; Han Hu; Ning Tang; Chunling Zhang; Wei Liang; Minwei Wang
Journal:  Pharm Res       Date:  2006-12-14       Impact factor: 4.200

6.  Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury.

Authors:  S Sanz; J B Pucilowska; S Liu; C M Rodríguez-Ortigosa; P K Lund; D A Brenner; C R Fuller; J G Simmons; A Pardo; M-L Martínez-Chantar; J A Fagin; J Prieto
Journal:  Gut       Date:  2005-01       Impact factor: 23.059

Review 7.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

8.  Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis.

Authors:  Anne-Charlotte de Gouville; Valerie Boullay; Gael Krysa; Julia Pilot; Jean-Marie Brusq; Florence Loriolle; Jean-Michel Gauthier; Stephen A Papworth; Alain Laroze; Françoise Gellibert; Stephane Huet
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

9.  Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C.

Authors:  Jordi Colmenero; Ramón Bataller; Pau Sancho-Bru; Marlene Domínguez; Montserrat Moreno; Xavier Forns; Miquel Bruguera; Vicente Arroyo; David A Brenner; Pere Ginès
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-23       Impact factor: 4.052

10.  Immunomodulatory effects of plasminogen activators on hepatic fibrogenesis.

Authors:  A A Higazi; M El-Haj; A Melhem; A Horani; O Pappo; C E Alvarez; N Muhanna; S L Friedman; R Safadi
Journal:  Clin Exp Immunol       Date:  2008-02-14       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.